FINWIRES · TerminalLIVE
FINWIRES

Hualan Gets China Clinical Trial Approval for Influenza Jab

By

China's drug regulator approved Hualan Biological Engineering (SHE:002007) subsidiary Hualan Biological Vaccine's clinical trial for its novel adjuvanted influenza virus split vaccine.

The vaccine helps with immunity against influenza, especially in elderly and immunocompromised patients, according to a Saturday disclosure to the Shenzhen bourse.

Related Articles